Article

Factors affecting willingness to provide buprenorphine treatment.

The New York Academy of Medicine, Division of Health Policy, New York, NY 10029, USA.
Journal of substance abuse treatment (Impact Factor: 2.9). 09/2008; 36(3):244-51. DOI: 10.1016/j.jsat.2008.06.006
Source: PubMed

ABSTRACT Buprenorphine is an effective long-term opioid agonist treatment. As the only pharmacological treatment for opioid dependence readily available in office-based settings, buprenorphine may facilitate a historic shift in addiction treatment from treatment facilities to general medical practices. Although many patients have benefited from the availability of buprenorphine in the United States, almost half of current prescribers are addiction specialists suggesting that buprenorphine treatment has not yet fully penetrated general practice settings. We examined factors affecting willingness to offer buprenorphine treatment among physicians with different levels of prescribing experience. Based on their prescribing practices, physicians were classified as experienced, novice, or as a nonprescriber and asked to assess the extent to which a list of factors impacted their prescription of buprenorphine. Several factors affected willingness to prescribe buprenorphine for all physicians: staff training; access to counseling and alternate treatment; visit time; buprenorphine availability; and pain medications concerns. Compared with other physicians, experienced prescribers were less concerned about induction logistics and access to expert consultation, clinical guidelines, and mental health services. They were more concerned with reimbursement. These data provide important insight into physician concerns about buprenorphine and have implications for practice, education, and policy change that may effectively support widespread adoption of buprenorphine.

0 Followers
 · 
136 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unobserved, or "home" buprenorphine induction is common in some clinical practices. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This review summarizes the literature on the feasibility and acceptability, safety, effectiveness, and prevalence of unobserved induction.
    Journal of Addiction Medicine 09/2014; 8(5):299-308. DOI:10.1097/ADM.0000000000000059 · 1.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Buprenorphine follows the success of methadone as another milestone in the history of treatment for opioid addiction. Buprenorphine can be used in an office-based setting where it is clearly effective, highly accepted by patients and has a favorable safety profile and less abuse potential. However, the adoption of buprenorphine treatment has been slow in the USA.Areas covered: This article first reviews the history of medication-assisted opioid addiction treatment and the current epidemic opioid addiction, followed by a review of the efficacy, pharmacology and clinical prescription of buprenorphine in office-based care. We then explore the possible barriers in using buprenorphine and the ways to overcome these barriers, including new formulations, educational programs and policy regulations that strike a balance between accessibility and reducing diversion.Expert opinion: Buprenorphine can align addiction treatment with treatments for other chronic medical illnesses. However, preventing diversion will require graduate and continuing medical education and integrated care models for delivery of buprenorphine to those in need.
    Expert Opinion on Pharmacotherapy 08/2014; 15(15). DOI:10.1517/14656566.2014.955469 · 3.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unobserved or "home" buprenorphine induction has become a common clinical practice. Patients take the initial and subsequent doses of buprenorphine after, rather than during, an office visit. This clinical case summarizes an unobserved induction onto buprenorphine in a typical new patient. We review the core issues surrounding patient selection, feasibility, logistics, safety, and effectiveness of unobserved buprenorphine induction. Prescribers, treatment providers, policy makers, and patients should weigh the benefits of observed induction (maximum clinical supervision) with the reduced resource burden, flexibility, and comparable safety of unobserved induction.
    Journal of Addiction Medicine 09/2014; 8(5):309-314. DOI:10.1097/ADM.0000000000000060 · 1.71 Impact Factor

Full-text (2 Sources)

Download
52 Downloads
Available from
May 19, 2014